Efficacy of Substance Removal by Immunoadsorption With a Selective Plasma Separator
暂无分享,去创建一个
M. Nangaku | K. Tsuchiya | K. Nitta | N. Hanafusa | Hiroko Yamamoto | Satoko Sakurai | Toshihiro Torato | M. Tamachi
[1] T. Okado,et al. Removal Characteristics of Immunoadsorption With the Immusorba TR‐350 Column Using Conventional and Selective Plasma Separators , 2016, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[2] T. Okado,et al. Removal Characteristics of Immunoglobulin G Subclasses by Conventional Plasma Exchange and Selective Plasma Exchange , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[3] T. Okado,et al. Removal Kinetics of Antibodies Against Glutamic Acid Decarboxylase by Various Plasmapheresis Modalities in the Treatment of Neurological Disorders , 2014, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[4] T. Rai,et al. Solute Removal Capacity of High Cut‐Off Membrane Plasma Separators , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[5] M. Nangaku,et al. Differences in Reduction of Coagulation Factor XIII (F13) Between Immunoadsorption Plasmapheresis and Double Filtration Plasmapheresis , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[6] N. Hanafusa. Theoretical Basis of Pathogenic Substance Removal During Plasmapheresis , 2011, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[7] A. Kaplan,et al. The plasma bradykinin-forming pathways and its interrelationships with complement. , 2010, Molecular immunology.
[8] F. Dekker,et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 , 2008, Journal of Neuroimmunology.
[9] N. Shibuya,et al. Plasmapheresis affects T helper type-1/T helper type-2 balance of circulating peripheral lymphocytes. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[10] G. Matic,et al. Background and indications for protein A-based extracorporeal immunoadsorption. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[11] F. Rosenow,et al. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis. , 2000, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[12] B. Krämer,et al. Extracorporal therapy with AN69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? , 2000, Clinical nephrology.
[13] D. Hofmann,et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. , 2000, Artificial organs.
[14] G Samuelsson,et al. What's happening? Protein A columns: current concepts and recent advances. , 1999, Transfusion science.
[15] H. Okada,et al. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[16] M. Yoshida,et al. Immusorba TR and Immusorba PH: basics of design and features of functions. , 1998, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.
[17] K. Hirata,et al. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption , 1998, Journal of the Neurological Sciences.
[18] M. Takamori,et al. Specific removal of antiacetylcholine receptor antibodies in patients with myasthenia gravis , 1996 .
[19] N. Yuki. Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome , 1996, Neurology.
[20] M. Takamori,et al. Specific removal of anti-acetylcholine receptor antibodies in patients with myasthenia gravis. , 1996, Transfusion science.
[21] R. Watt,et al. Therapeutic protein A immunoadsorption. A review , 1990 .